Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
Conditions: Human Papilloma Virus Infection; Salivary Gland Squamous Cell Carcinoma; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Tongue CancerInterventions: Drug: veliparib; Other: placebo; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy; Drug: hydroxyurea; Drug: paclitaxel; Drug: carboplatinSponsor: National Cancer Institute (NCI)Recruiting - verified August 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials